Skip to content
Study details
Enrolling now

Limiting AAA With Metformin (LIMIT) Trial

Stanford University
NCT IDNCT04500756ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

314

Study length

about 6.3 years

Ages

50–95

Locations

1 site in CA

What this study is about

This trial is testing whether metformin, a medication, can help slow the growth of abdominal aortic aneurysms (AAAs). AAAs are abnormal enlargements of the aorta in the abdomen that carry a risk of rupture and life-threatening bleeding. The goal is to determine if metformin prevents AAAs from growing larger.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Placebo
  • 2.Take Metformin

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

metformin (Biguanide antidiabetic; reduces liver glucose production and improves insulin sensitivity)

Drug routes

oral

Endpoints

Secondary: All-cause mortality, Change from baseline in Living with Abdominal Aortic Aneurysm (AAA) Survey, Change from baseline in Short Form (SF-36) health survey